Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization

• Status: Withdrawn
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The success of in vitro fertilization is based mainly on uterine implantation embryo. An excessive uterine contractility may interfere with implantation by a movement of the embryo in the uterus. The inhibition of the uterine contractility may have a positive effect on success rate of in vitro fertilization. It is through parenteral injection of glucagon and its spasmolytic effect on various smooth muscles and thereby on the uterine muscle, at the time of embryo transfer, the investigators intend to improve the pregnancy rates obtained after IVF.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinique Ovo; OVO R & D
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Women doing fertility treatment at the clinic ovo or fertility clinic of CHUM

• Less than 40 years old

• Women with stimulate in vitro fertilization cycle

• Women able to give her consent

Exclusion Criteria:

• Body mass index > 35 kg/m2

• Women with diabetes

• Women with hypertensive disorders

• Women with a blood pressure greater or equal to 140/90 mmHg at the randomization visit

• Cons-indication to taking Glucagon:

• Hypersensitivity to product

• Pheochromocytoma or history of pheochromocytoma

• Insulinoma

• Taking a beta-blocker (drug interactions)